

(Under Corporate Insolvency Resolution Process)

December 13, 2017

**BSE Limited
Corporate Relationship Department
1st floor, New Trading Ring
Rotunda Building, P J Towers
Dalal Street, Fort
Mumbai - 400 001**

Dear Sir/Madam


In accordance with the requirements of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are pleased to inform that Orchid has received ANDA approval from US FDA for Aripiprazole Orally-Disintegrating Tablets USP, 10 mg and 15 mg today (ANDA Ref. No. 202547).

Aripiprazole Orally-Disintegrating Tablets are atypical antipsychotic, indicated in the treatment symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression).

Kindly take the above information on your records.

Thanking you,

Yours faithfully,



L Chandrasekar
Executive VP – Finance & Secretary